Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, +11

Journal of Clinical Oncology

Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

William Plunkett, Peng Huang, Yi-Zheng Xu, +3

PubMed

Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

Ephraim S. Casper, Mark R. Green, David P. Kelsen, +5

Investigational New Drugs

OncologyPhase Ii TrialPancreatic CancerMedicinePancreatic Surgery +3

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

Volker Heinemann, Yi-Zheng Xu, Sherri Chubb, +4

Molecular Pharmacology

Gemcitabine: preclinical pharmacology and mechanisms of action.

William Plunkett, Peng Huang, C. E. Searcy, +1

PubMed

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

Heather Anderson, Birthe Lund, Flemming W. Bach, +3

Journal of Clinical Oncology

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.

Raymond P. Abratt, W. R. Bezwoda, Geoffrey Falkson, +3

Journal of Clinical Oncology

World Health OrganizationSurgical OncologyPhase Ii StudyPharmacotherapyMetronomic Chemotherapy +16

Advanced breast cancer: a phase II trial with gemcitabine.

J Carmichael, K. Possinger, P. Phillip, +4

Journal of Clinical Oncology

Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.

Volker Heinemann, Yi-Zheng Xu, Sherri Chubb, +4

PubMed

Cell DeathCell CultureDfdctp EliminationChemical BiologyCellular Physiology +17

2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase

C. H. Baker, Jennifer A. Banzon, J. Martin Bollinger, +6

Journal of Medicinal Chemistry